

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended): A method for diagnosing, or identifying a predisposition to the development of, ~~age-related~~ a macular degeneration related disorder in a subject, comprising detecting in a biological sample from the subject the presence or abnormal levels of an autoantibody against, or an immune complex containing, ~~at least one macular degeneration associated molecule~~ *fibulin-3, beta-crystallin A2, beta-crystallin A3, beta-crystallin A4, beta-crystallin S, calreticulin, 14-3-3 protein epsilon, or serotransferrin* or an antigenic fragment thereof.
2. (Currently Amended): The method of claim 1, wherein said macular degeneration related disorder is age-related macular degeneration or Malattia Leventinese ~~associated molecule is selected from the group consisting of fibulin-1, fibulin-2, fibulin-3, fibulin-4, fibulin-5, fibulin-6, vitronectin,  $\beta$  crystallin A2,  $\beta$  crystallin A3,  $\beta$  crystallin A4,  $\beta$  crystallin S, glucose-regulated protein 78 kD (GRP-78), calreticulin, 14-3-3 protein epsilon, complement 1q binding protein/hyaluronic acid binding protein, serotransferrin, albumin, keratin, pyruvate carboxylase, type IV collagen, elastin, C reactive protein (CRP), clusterin, metalloelastase, and villin-2.~~
3. (Currently Amended): The method of claim 1, wherein the detecting comprises contacting the biological sample with *fibulin-3* ~~said at least one macular degeneration associated molecule~~ or an antigenic fragment thereof, and detecting a specific interaction between the autoantibody and the *fibulin-3* ~~at least one macular degeneration associated molecule~~ or an antigenic fragment thereof.

4. (Currently amended): The method of claim 1, wherein the detecting comprises ~~precipitating the immune complex from the biological sample~~ contacting the biological sample with serotransferrin or an antigenic fragment thereof, and detecting a specific interaction between the autoantibody and the serotransferrin or antigenic fragment thereof.

5. (Original): The method of claim 1, further comprising detecting a level of the autoantibody or immune complex in a control subject and comparing levels of the autoantibody or immune complex in the subject and the control subject.

6. (Original): The method of claim 1, wherein said biological sample is a urine, eye fluid, blood plasma, serum, whole blood, or lymph fluid from the subject.

7. (Currently Amended): The method of claim ~~3~~ 1, further comprising the step of precipitating a complex formed between the autoantibody and the ~~at least one macular degeneration-associated molecule~~ *fibulin-3, beta-crystallin A2, beta-crystallin A3, beta-crystallin A4, beta-crystallin S, calreticulin, 14-3-3 protein epsilon, or serotransferrin* or an antigenic fragment thereof before the detecting step.

8-14 (Cancelled).

15. (Currently Amended): The method of claim 1, further comprising examining ~~the a~~ subject with an ophthalmologic procedure after detecting the presence or abnormal levels of an autoantibody against *fibulin-3, beta-crystallin A2, beta-crystallin A3, beta-crystallin A4, beta-crystallin S, calreticulin, 14-3-3 protein epsilon, or serotransferrin* in a biological sample from the subject.

16-20 (Cancelled).

21. (Currently Amended): The method of claim ~~1~~ 20, wherein said biological sample is a urine, eye fluid, blood plasma, serum, lymph fluid, or whole blood from the subject.

22. (Currently Amended): The method of claim ~~4~~ 20, wherein the detecting comprises contacting the biological sample with ~~vitronectin~~ serotransferrin or an antigenic fragment of ~~vitronectin~~ serotransferrin, and detecting a specific interaction between the autoantibody and ~~vitronectin~~ serotransferrin or a specific interaction between the autoantibody and the antigenic fragment of ~~vitronectin~~ serotransferrin.

23-32 (Cancelled).

33. (New): The method of claim 2 wherein the macular degeneration related disorder is age-related macular degeneration.

34. (New): The method of claim 2 wherein the macular degeneration related disorder is Malattia Leventinese.